SD-101 is a TLR-9 agonist that has been studied in combination with pembrolizumab in patients with advanced melanoma without prior exposure to anti-PD-1 therapy under a phase IB/II study (SYNERGY-001/KEYNOTE-184). This evidence concerns the gene TLR9 and melanoma.